Pair page
Glumitide with Mazdutide
Mechanism-tag overlap and published literature for Glumitide and Mazdutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-gip-receptor-agonist
incretin-peptide
dual-glp-1-glucagon-receptor-agonist
Quick facts
Glumitide
Mazdutide
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Glumitide | Pratt EJ, Roell W, Knop FK, Urva S, et al. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. PMID: 41391569; PMC: PMC12808604. PMID 41391569 | |
| 2024 | Glumitide | Knop FK, Pratt EJ, Roell W, et al. A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy. Diabetes Obes Metab. 2024. DOI: 10.1111/dom.15875. (NCT05444569 — co-adm… PMID doi:10.1111/dom.15875 | |
| 2023 | Glumitide | Knop FK, Urva S, Rettiganti M, Benson C, Roell W, Mather KJ, Haupt A, Pratt EJ. 56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting. Diabetes 2023;72(Supplement_1):56-OR. (ADA scientific session abstract… PMID doi:10.2337/db23-56-OR | |
| 2025 | Mazdutide | Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736. DOI: 10.1056/NEJMoa2411528. (Pivotal GLORY-1 Phase 3 publication, May 2025.) PMID 40421736 | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, Qian L, et al; DREAMS-1 Investigators. Mazdutide in Chinese adults with untreated type 2 diabetes: DREAMS-1 Phase 3 trial. Nature. 2025. (Accelerated Article Preview publication, late 2025; part of back-to-back Nature release.) | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, et al; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral medication: DREAMS-2 Phase 3 trial. Nature. 2025. (Back-to-back with DREAMS-1.) | human trial, Phase 3 |
| 2025 | Mazdutide | Innovent Biologics press release. Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature. November 2025. | human trial, Phase 3 |
| 2025 | Mazdutide | BioSpace press release. Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3). May 15, 2025. | human trial, Phase 3 |
| 2018 | Mazdutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10… PMID 29945726 | human trial, Phase 2 |
| 2022 | Mazdutide | Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical… PMID 36337827 | human trial, Phase 1 |
| 2022 | Mazdutide | Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID: 35750890. (Phase 1b / dose… PMID 35750890 | human trial, Phase 1 |
| 2025 | Mazdutide | Innovent Biologics press release. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 19, 2025. | human study |
| 2017 | Mazdutide | Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. PMID: 28733905. (Class review.) PMID 28733905 | human study |
| 2009 | Mazdutide | Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266. PMID: 19602537. (Preclinical proof-of-concept for the dual-agonist class.) PMID 19602537 | preclinical, in vivo |
| 2018 | Mazdutide | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. (GLP-1 mechanism framework.) PMID 29617641 | research article |
Related pair pages
More research context
Frequently asked
Have Glumitide and Mazdutide been studied together?
No co-administration studies between Glumitide and Mazdutide are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Glumitide and Mazdutide share?
Glumitide and Mazdutide share these mechanism tags on their Kalios profiles: incretin-peptide. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Glumitide and Mazdutide?
Glumitide: Investigational New Drug (Phase 1). Mazdutide: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Glumitide and Mazdutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Glumitide profile and the Mazdutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026